Home - Mesoblast Ltd
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases …
Mesoblast - Wikipedia
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by …
Product Candidates Overview - Mesoblast Ltd
Mesoblast’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. Proprietary media formulations, advances in development of 3D …
Mesoblast Files Request for Type B Meeting with FDA to Discuss ...
1 天前 · Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA …
Overview - Mesoblast Ltd
Mesoblast is using its proprietary technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex diseases resistant to conventional standard of …
After two rejections, FDA approves Mesoblast's GVHD cell therapy
2024年12月19日 · After two rejections from the FDA, Mesoblast has finally gained approval for its first drug, Ryoncil, a cell therapy for graft versus host disease.
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved …
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today …
Mesoblast finally pushes GvHD cell therapy over finish line
4 天之前 · Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children undergoing HSCT.
First Three Children to Commence Treatment With Ryoncil®
4 天之前 · About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering …
Mesoblast Files Request for Type B Meeting with FDA to
1 天前 · Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms.